| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01493414 | INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. | PHASE3 | COMPLETED | 2,233 | — | — | Aug 16, 2011 | Jan 26, 2017 | Apr 26, 2019 | 273 | Algeria, Argentina +23 |
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant regardless of causal relationship to study drug and regardless whether study drug has been administered. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A non-serious AE is any AE that does not meet the criteria above.
| Arm | Type | Description |
|---|---|---|
| INC424 | EXPERIMENTAL | 5 - 25 mg twice a day (BID) |
| Name | Type | Description |
|---|---|---|
| INC424 | DRUG | All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally. |
Main Inclusion Criteria: 1. Patients must not be eligible for another ongoing INC424 clinical trial. 2. Patients must be diagnosed with PMF, PPV MF or PET-MF, according to the 2008 revised International Standard Criteria, irrespective of JAK2 mutation status.. 3. Patients with PMF requiring therapy...